Sofosbuvir Plus Ribavirin for the Treatment of Hepatitis C Virus Genotype 2 in Korea: What’s the optimal dosage of ribavirin in real‐world setting?
| Autor: | Ju Yeon Cho, Sung Wook Lim, Jae Hyun Yoon, Chung Hwan Jun, Hyun A Cho, Man Woo Kim, Sung Kyu Choi, Ji Ho Seo, Sung Bum Cho |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Cirrhosis Adolescent Genotype Sustained Virologic Response Sofosbuvir Anemia Hepatitis C virus Hepacivirus medicine.disease_cause Antiviral Agents 030226 pharmacology & pharmacy Gastroenterology Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Republic of Korea Ribavirin medicine Humans 030212 general & internal medicine Adverse effect Aged Retrospective Studies Aged 80 and over Dose-Response Relationship Drug business.industry Incidence (epidemiology) virus diseases Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease digestive system diseases Treatment Outcome chemistry Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Journal of Digestive Diseases. |
| ISSN: | 1751-2980 1751-2972 |
| DOI: | 10.1111/1751-2980.12695 |
| Popis: | This study aimed to investigate the efficacy and safety of sofosbuvir plus ribavirin for the treatment of hepatitis C virus (HCV) genotype 2 infection and to determine the optimal ribavirin dosage.From May 2016 to March 2017, 199 patients received sofosbuvir plus ribavirin treatment for HCV genotype 2 infection at four centers in Jeollanam-do Province, Korea. After excluding patients lost to follow-up and those with insufficient data, we retrospectively assessed the data for 194 patients. The treatment efficacy and safety of sofosbuvir plus ribavirin were evaluated.A sustained virological response was achieved in 189 patients (intention-to-treat [ITT] 97.4%; per protocol [PP]: 99.5%, both at 12 and 24 weeks) whose average ribavirin dosage was 937.1 mg/day. The most frequent adverse event was anemia (17.5%), and its incidence significantly increased (P0.001) with a higher ribavirin dosage per body weight. Discontinuation of ribavirin or dosage reduction occurred in 27 (14.2%). The ribavirin dosage reduction rate increased at a dosage of15 mg/kg (area under the receiver operating characteristic curve 0.652, 95% confidence interval [CI] 0.54-0.76, P = 0.01). Multivariate analysis showed that age ≥70 years, with liver cirrhosis, and female gender were associated with ribavirin dosage reduction.Remarkable outcomes were attained in patients with HCV genotype 2 infection treated with sofosbuvir plus ribavirin. Age ≥70 years, with liver cirrhosis, and female gender were associated with ribavirin dosage reduction. Thus, sustained virological response can be achieved with1000 mg of ribavirin, with an optimal dosage of 15 mg/kg. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|